Ionis Pharmaceuticals, a biotechnology company based in Carlsbad, California, completed the acquisition of the remaining 24% stake in Akcea Therapeutics, a development and commercialization company, for $446m. "This acquisition is another step forward in Ionis' evolution and creates a stronger, more efficient organization to the benefit of all stakeholders. We believe becoming one company – with one vision and one set of strategic priorities, led by one team – will deliver significant strategic value, enhancing the future success of our company, accelerating our next phase of growth and positioning us to most effectively deliver our medicines to patients. Following the completion of the transaction, Ionis will retain more value from Akcea's rich pipeline and commercial products, further strengthening our financial position and supporting continued investments in our future," Brett Monia, Ionis CEO.